Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | VNN1 | O95497 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13610472 | 0.79 | RAB9A (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19RAB9A | |
| SCHEMBL13610480 | 0.79 | SMN1; SMN2 (0.46) | CYP1A2CYP2C9CYP2C19RAB9AHSD17B10 | |
| SCHEMBL13610513 | 0.77 | RAB9A (0.45) | RAB9AKMT2A | |
| SCHEMBL19940168 | 0.74 | DAO (0.40) | DAORAB9AKMT2AVNN1 | |
| SCHEMBL13610495 | 0.74 | DAO (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19DAO | |
| SCHEMBL13610503 | 0.72 | PDK1 (0.57) | RAB9AHSD17B10 | |
| SCHEMBL13610496 | 0.72 | RAB9A (0.35) | CYP1A2CYP3A4CYP2C9CYP2C19DAO | |
| SCHEMBL13610517 | 0.71 | FBP1 (0.40) | DAORAB9ACYP2D6 | |
| SCHEMBL13610497 | 0.71 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C9CYP2C19RAB9A | |
| SCHEMBL11575673 | 0.71 | DAO (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742635-B1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | ACEA BIOSCIENCES INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-8334316-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334316-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-7622507-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622507-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090192146-A1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | ACEA BIOSCIENCES, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090192146-A1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | ACEA BIOSCIENCES, INC. (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192146-A1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | TST, CTH, CBS | CYP1A2 3924/4885CYP3A4 3786/4885CYP2C9 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.